US2015099007A1PendingUtilityA1

Method and System for Treatment of Biological Tissue

70
Assignee: CORMATRIX CARDIOVASCULAR INCPriority: Jan 18, 2006Filed: Dec 17, 2014Published: Apr 9, 2015
Est. expiryJan 18, 2026(expired)· nominal 20-yr term from priority
Inventors:Robert G. Matheny
A61K 31/4174A61L 27/3633A61K 31/40A61L 27/367A61L 27/3873A61L 2430/20A61K 31/366A61P 9/10A61K 31/7048A61K 31/4418A61K 31/404A61K 31/505A61P 9/00A61K 31/7056A61K 9/0019A61K 31/43A61K 45/06A61K 48/00A61K 35/34A61B 17/205A61K 38/14A61K 31/165A61K 35/38A61K 31/22A61K 31/47A61L 27/3683A61B 2017/00247A61L 2400/06A61K 31/722A61P 43/00A61K 31/65A61L 27/3834A61L 27/3804
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes mesothelial tissue.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition for treating damaged biological tissue, comprising:
 an extracellular matrix (ECM) composition comprising acellular mesothelial tissue, wherein, when said ECM composition is administered to said damaged biological tissue, said ECM composition induces bioremodeling and regeneration of new biological tissue.   
     
     
         2 . The composition of  claim 1 , wherein said ECM composition further comprises an exogenously added growth factor selected from the group consisting of transforming growth factor beta (TGF-beta), fibroblast growth factor-2 (FGF-2) and vascular epithelial growth factor (VEGF). 
     
     
         3 . The composition of  claim 1 , wherein said ECM composition further comprises a fluidizing component selected from the group consisting of water and saline.

Join the waitlist — get patent alerts

Track US2015099007A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.